BioIntelliSense
- Industry
- Health Monitoring and Clinical Intelligence
- Founded Year
- 2018
- Headquarters
- Golden, Colorado, United States
- Employee Count
- 150
Key People
- James Mault, MD FACS - Founder, CEO & Chairman
- David Wang - Co-Founder & Chief Technology Officer
- Justin Rice - Director, NPI Program Management
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in medical technology and healthcare.
The leadership team, including Dr. James Mault and David Wang, brings extensive experience in medical technology and healthcare, positioning the company for strategic growth and innovation.
- Clinical Need
-
Aspect: Very Strong
Summary: The company's products address a critical need for continuous health monitoring and remote patient care.
BioIntelliSense's wearable devices provide continuous, medical-grade monitoring, meeting the growing demand for remote patient monitoring solutions, especially in the context of chronic disease management and pandemic response.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has several competitors, but BioIntelliSense maintains a strong position.
While the remote patient monitoring market includes established players like Philips and Medtronic, BioIntelliSense's FDA-cleared devices and data services offer a competitive edge.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves moderate complexity with manageable challenges.
Developing and deploying wearable health monitoring devices requires technical expertise, but the challenges are predictable and within the company's capabilities.
- Patent
-
Aspect: Strong
Summary: The company has a solid patent portfolio supporting its innovations.
BioIntelliSense's intellectual property, including FDA-cleared devices, provides a competitive advantage and protects its technological innovations.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding to support its growth.
With a $45 million Series B financing round led by prominent investors, BioIntelliSense is well-positioned to scale its operations and expand its market presence.
- Regulatory
-
Aspect: 510k/PMA
Summary: The company's products have received necessary regulatory clearances.
The FDA clearance of BioIntelliSense's devices ensures compliance with regulatory standards, facilitating market entry and adoption.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 4.7
- Segment CAGR
- 3.6%
- Market Segment
- Remote Patient Monitoring
- Market Sub Segment
- Wearable Health Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.70 |
| 3 | 1.64 |
| 4 | 3.29 |
| 5 | 4.70 |
Key Takeaway
BioIntelliSense is well-positioned in the growing remote patient monitoring market, leveraging its innovative wearable devices and strong leadership to address critical healthcare needs.